MediPaper Hong Kong

Medical Communications &Health News

Therapeutic Areas

IMMUNO-ONCOLOGY ARTICLES

ASCO 2018 breast cancer TNBC MBC ABC ASCO18 PHEREXA D-CARE ABCSG-18 ASTRRA TEXT SOFT MONARCH-2 MONALEESA-3 SANDPIPER BOLERO-6 TOPACIO KEYNOTE-162 TONIC TOPACIO GeparNeuvo

©eraxion / 123RF Stock Photo

June 19, 2018/by Stijn van den Borne, MSc

ASCO 2018 Breast Cancer: The ASCO18 breast cancer track summarised

Breast cancer: a front-runner when it comes to the development of novel therapeutic strategies. With the advent of newer targeted- and immunotherapies, oncologists have an increment of options to offer their patients. The American Society of Clinical Oncology’s (ASCO) 2018 Breast Cancer track offered an extensive look at the latest advancements and updates from on-going trials covering the various subtypes of breast cancer.

U.S. FDA approved immunecheckpoint inhibitors U.S. FDA approved immunotherapies for cancer U.S. FDA approved immunotherapies for cancer

©pixologic / 123rf stock photo

June 18, 2018/by Stijn van den Borne, MSc

U.S. FDA Approved Immune-Checkpoint Inhibitors Updated 18-Jun-2018

May 18, 2018/by Stijn van den Borne, MSc

FDA safety alert: use of immunotherapy in metastatic urothelial cancer with low PD-L1 expression

IMPower150 Reck Socinski ELCC AACR 2018 firstline atezolizumab bevacizumab chemotherapy non-squamous nsclc

bravajulia / 123RF Stock Photo

May 10, 2018/by Stijn van den Borne, MSc

AACR 2018: first-line atezolizumab, bevacizumab plus chemotherapy active in non-squamous NSCLC

US FDA approved CAR-t cell BiTE DAR-T cell CD19 Immunotherapies blinatumomab axicabtagene ciloleucel tisagenlecleucel

May 2, 2018/by Stijn van den Borne, MSc

US FDA approved CAR-T cell and BiTE immunotherapy - Updated 2-May-2018

ONCOLOGY ARTICLES

ASCO18 ASCO 2018 HCC hepatocellular carcinoma liver cancer pembrolizumab KEYTRUDA atezolizumab TECENTRIQ PD-1 PD-L1 immunecheckpoint immunotherapy ramucirumab cabozantinib KEYNOTE-224 SCRUM-Japan GI-SCREEN CELESTIAL REACH-2

© krishnacreations / 123RF Stock Photo

June 8, 2018/by Anne John Michael

ASCO 2018 HCC: The ASCO18 hepatocellular cancer track summarised

This year’s American Society of Clinical Oncology (ASCO) annual meeting includes two Phase III studies in the second-line treatment of the disease. Moreover, data with several immune-checkpoint inhibitors were presented, including the KEYNOTE-224 with pembrolizumab. Welcome to the summary of the ASCO 2018 HCC track.

AACR 2018 First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Hywards / 123RF Stock Photo

April 21, 2018/by Stijn van den Borne, MSc

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

NCT02578680 Keynote189 AACR 2018 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

krishnacreations / 123RF Stock Photo

April 19, 2018/by Stijn van den Borne, MSc

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Non-squamous NSCLC

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

April 10, 2018/by Stijn van den Borne, MSc

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Herbert Loong on irAEs Immunotherapy (I-O) and New Onset Diabetes or immune-mediated diabetes

April 6, 2018/by Stijn van den Borne, MSc

I-O in Special Populations: Diabetes and Concomitant Steroids

MEMBERS ONLY

irAE immune-related adverse events immune-mediated adverse events hepatitis pneumonitis rash diabetes_small

©invincible7 / 123RF Stock Photo

CONFERENCE HIGHLIGHTS

ASCO 2018 ASCO18 pembrolizumab nivolumab durvalumab atezolizumab avelumab ipilimumab tremelimumab olaparib rucaparib niraparib PARP palbociclib ribociclib abemaciclib CDK46 osimertinib cabozantinib lenvatinib lorlatinib

©American Society for Clinical Oncology (ASCO)

aacr2018 american association for cancer research annual meeting 2018 AACR 2018 AACR annual meeting 2018

©American Association for Cancer Research

CSA2017-0-中华医学会第25-次全国麻醉学术年会-2017-郑州-25th-Annual-Meeting-of-the-Chinese-Society-of-Anaesthesiology

©Chinese Society for Anesthesiology

© European Society for Medical Oncology

ASCO 2016 annual meeting

©American Society of Clinical Oncology

©American College of Cardiology

ONCOLOGY ARTICLES (Cont’d)

Crizotinib beneficial for East-Asian NSCLC-patients with ROS1 alterations crizotinib asian crizotinib ros1 crizotinib asian nsclc patients crizotinib asian non-small cell lung cancer patients

April 4, 2018/by Stijn van den Borne, MSc

Crizotinib beneficial for East-Asian NSCLC patients with ROS1 alterations

Crizotinib in Asian NSCLC patients with ROS1 alterations was associated with a 71.7% objective response rate (ORR) with a median duration of response (DOR) of 19.7 months (95% CI, 14.1 months - not reached). Learn more about the results with crizotinib in East-Asian non-small cell lung cancer (NSCLC) patients harbouring c-ros oncogene 1 (ROS1) rearrangements.

immunotherapy I-O immunooncology nivolumab npc opdivo nasopharyngeal carcinoma brigette ma CUHK phase II nci-9742 study JCO journal of clinical oncology

March 31, 2018/by Stijn van den Borne, MSc

Nivolumab for NPC: immunotherapy active in nasopharyngeal carcinoma (NCI-9742)

Making sense of immunotherapy in NSCLC

March 26, 2018/by Stijn van den Borne, MSc

Making sense of 1st-line immunotherapy in non-small cell lung cancer (NSCLC)

Symposium Highlight 5HT3 NK1 Palonosetron Netupitant CINV Chemotherapy-induced Nausea and Vomiting

January 30, 2018/by Stijn van den Borne, MSc

Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control

manuela schmidinger sutent sunitinib ae management manuela schmidinger manuela schmidinger sutent sunitinib side-effect management sutent sunitinib toxicity management Sutent Sunitinib AE management toxicity management side-effect management sorafenib pazopanib axitinib regorafenib vandetanib cabozantinib lenvatinib bevacizumab VEGFR VEGF renal cell carcinoma RCC kidney cancer renal cell cancer schmidinger

November 29, 2017/by Stijn van den Borne, MSc

Achieving Long-Term Survival in the First-Line Treatment of Metastatic Renal Cell Carcinoma; A Balancing Act of Efficacy and Side-Effects

2016 pancreatic cancer awareness month IMM-101 plus Gemcitabine medipaper medical communications medical writer hire healthcare writers hong kong

November 20, 2017/by Stijn van den Borne, MSc

Do you know your lifetime risk on Pancreatic Cancer?

HKBCF luminal breast cancer can cdk46 inhibition by palbociclib improve on chemotherapy medipaper medical writer hong kong

October 25, 2017/by Stijn van den Borne, MSc

Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?

Nivolumab Renal Cell Cancer Symposium Highlight

September 19, 2017/by Stijn van den Borne, MSc

Nivolumab for Renal Carcinoma: Getting the Most Out of PD-1 Immunotherapy

adjuvant hormonal therapy

July 5, 2017/by Stijn van den Borne, MSc

Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?

2017 CICS immunooncology annual meeting oncology medical writer medipaper medical communications

June 21, 2017/by Stijn van den Borne, MSc

Interested in Attending an Immunooncology Conference?

Latest global trends of health measure and impact on survival rate

August 16, 2017/by Stijn van den Borne, MSc

Latest global trends of health measure and impact on survival rate

Lack of strength and diabetes are becoming epidemic in the ageing population, and patients often ignore early signs and are unaware how to prevent these problems.

scientific symposium highlights optimisation of aerosol delivery in patients with poor asthma control aerosol delivery asthma

July 18, 2017/by Stijn van den Borne, MSc

Optimisation of aerosol delivery in patients with poor asthma control

AMNOG Germany Pharmaceuticals Pricing Legislation MediPaper Medical Writer Hong Kong

December 15, 2016/by Stijn van den Borne, MSc

AMNOG: Germany Pharmaceuticals Pricing Legislation Overview

asco 2016 nivolumab medipaper medical communications

May 29, 2016/by Stijn van den Borne, MSc

ASCO16 Nivolumab (Opdivo©) Data

asco 2016 immune checkpoint inhibitors

April 4, 2016/by Stijn van den Borne, MSc

ACC2016: 8½ Important Cardiology Lessons Learned

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

June 14, 2018/by News Feed

Bevacizumab in combination with carboplatin and paclitaxel FDA approved for several types of gynaecological cancers

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

June 14, 2018/by News Feed

FDA approved pembrolizumab for 3rd-line PMBCL in adult and pediatric patients

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

June 13, 2018/by News Feed

FDA approved pembrolizumab for chemotherapy-refractory r/m cervical cancer with PD-L1 CPS ≥1

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

June 9, 2018/by News Feed

FDA approves venetoclax in 2nd-line for patients with CLL or SLL

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

June 6, 2018/by News Feed

FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

May 21, 2018/by News Feed

FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

May 16, 2018/by News Feed

Biosimilar epoetin alfa-epbx approved by FDA for the treatment of anemia due to chronic kidney disease, use of zidovudine for HIV, and concomitant myelosuppressive chemotherapy

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

May 7, 2018/by Stijn van den Borne, MSc

FDA approves daratumumab plus VMP for transplant ineligible myeloma patients

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

May 4, 2018/by News Feed

FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation

us fda approval medipaper medical communications agency medical writer agency apac asia pacific HK hong kong oncology CV neurology immunotherapy obesity diabetes specialty infectious

©United States Food and Drug Agency

May 1, 2018/by News Feed

Tisagenlecleucel CAR-T receives additional FDA Approval for DLBCL

©aquir / 123RF Stock Photo

April 30, 2018/by News Feed

FDA granted regular approval to dabrafenib and trametinib in combination for the adjuvant treatment of patients with BRAF V600E or V600K melanoma

©aquir / 123RF Stock Photo

April 19, 2018/by News Feed

FDA approved osimertinib for the 1st-line treatment of patients with EGFR exon 19 deletions or exon 21 L858R mutations positive metastatic non-small cell lung cancer (NSCLC)

© Copyright - MediPaper Medical Communications - Medical Communications & Health News